



FOR IMMEDIATE RELEASE

Immgenuity Inc., Announces the Appointment of Carol Brosgart, MD to its Scientific Advisory Board

Dover, Delaware, January 11, 2023 – Immgenuity, a biotech company focused on developing innovative immunotherapies, announced today that Dr. Carol Brosgart has joined its Scientific Advisory Board.

Dr. Brosgart brings over 30 years of experience in the field of infectious diseases and clinical research to our team. She has held leadership positions at a number of organizations, including the University of California, San Francisco (UCSF) where she is a professor and the California Department of Public Health. Dr. Brosgart has also been involved in the development and implementation of global public health initiatives, including HIV/AIDS prevention and treatment programs. She had a distinguished career at Gilead Biosciences where she was a VP of Medical Research, and has served on numerous scientific advisory boards, including those of the National Institutes of Health and the Centers for Disease Control and Prevention. With Dr. Brosgart's extensive experience and expertise, Immgenuity is well-positioned to continue its work in advancing the field of HIV research and improving global health outcomes.

“We are thrilled to have Dr. Brosgart join our Scientific Advisory Board. Dr. Brosgart joins a distinguished group of experts on Immgenuity's Scientific Advisory Board, which includes leaders in immunology, infectious diseases, drug development and vaccine development. Her expertise in HIV, infectious diseases and clinical research will be invaluable as we continue to develop innovative solutions for treating HIV with immunotherapies”, said Dr. Sateesh Apte, CEO of Immgenuity, Inc.

“I am excited to join Immgenuity's Scientific Advisory Board and contribute to the development of innovative solutions to addressing HIV persistence. I look forward to working with the talented team at Immgenuity to advance their mission and make a positive impact on public health”, said Dr. Brosgart.

About Immgenuity, Inc.

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

About IMTV014

Immgenuity's immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as “salvage therapy” in the multidrug resistant population.

Contact: Media Relations: media@immgenuity.com (302) 321-5844

Forward Looking Statements:

This press release contains “forward-looking statements” within the meaning of federal securities law, including statements concerning the company’s outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.